Studies early changes in CADASIL, an inherited disease affecting brain blood vessels
Observes how CADASIL, an inherited brain blood vessel disease, develops in adults over time.
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Atlanta, Chicago, Denver, Houston, Los Angeles, New York, Portland, Providence, Salt Lake City, San Antonio, San Francisco, and Seattle, United StatesSee the 12 sites
- Trial code
- Registry title
- Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
- Status
- Recruiting
- People taking part
- 660 people, planned
- Started
- 3 Jun 2022
- Expected to end
- Aug 2027
- Type of study
- Observational, 4 groups
- Treatments tested
- Study Procedures
- Record updated
- 15 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have CADASIL or are at risk for it, and also adults without the NOTCH3 gene change as healthy controls.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- CADASIL, diagnosed or at risk. Functional capacity less than 4 on the Modified Rankin Scale.
- Earlier treatment
- No prior treatment is required. All medications are allowed during the study.
- Biomarker or test result
- CADASIL participants: positive NOTCH3 genetic test, or positive skin biopsy, or willing to have a NOTCH3 test before enrolling. Healthy controls: negative NOTCH3 genetic test.
Main reasons for not taking part
- History of severe learning disability, intellectual disability, or other neurological disease or event not caused by CADASIL
- Serious alcohol or drug abuse within the past year
- Unwilling to have NOTCH3 genetic testing if there is no test on file
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Must be at least 18 years old
- Positive NOTCH3 genetic testing; OR a positive skin biopsy; OR a willingness to have a NOTCH3 genetic test completed prior to enrolling AND are at-risk for, or diagnosed clinically with, CADASIL
- Willing to commit to three in-person visits (a baseline visit, an 18-month follow-up, and a 36-month follow-up) and to remote visits as needed by phone, email, mail or internet
- Willing to provide documentation of all current medications to study team; All medications will be allowed throughout the course of study. Documentation of medications will be used for analyses to assess potential impact of medications on study outcomes
- Willing and able to undergo an MRI scan and blood draw at each in-person visit
- Must have a designated "study companion"; A "study companion" is someone who knows the participant well (has greater than or equal to 3 hours/month of contact with the CADASIL participant) and can provide additional information to the study team (either remotely or in-person)
- A functional capacity less than 4 on the Modified Rankin Scale
- Must meet same criteria as CADASIL participants, EXCEPT have negative NOTCH3 genetic testing
Who cannot take part
- History of severe learning disability, intellectual disability, or other neurological disease or event not attributable to CADASIL
- History of serious alcohol or drug abuse within the past year
- Unwilling to undergo NOTCH3 genetic testing if there is no test on file
Where in United States
- Georgia State University Research FoundationAtlanta, United StatesContact: Cadasil ConsortiumTaking people
- Loyola UniversityChicago, United StatesContact: Cadasil ConsortiumTaking people
- University of ColoradoDenver, United StatesContact: Cadasil ConsortiumTaking people
- University of Texas Health Science CenterHouston, United StatesContact: Cadasil ConsortiumNot yet recruiting
- University of CaliforniaLos Angeles, United StatesContact: Cadasil ConsortiumTaking people
- Columbia UniversityNew York, United StatesContact: Cadasil ConsortiumTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Cadasil ConsortiumTaking people
- Brown UniversityProvidence, United StatesContact: Cadasil ConsortiumTaking people
- University of UtahSalt Lake City, United StatesContact: Cadasil ConsortiumTaking people
- University of TexasSan Antonio, United StatesContact: Cadasil ConsortiumNot yet recruiting
- University of CaliforniaSan Francisco, United StatesContact: Cadasil ConsortiumTaking people
- University of WashingtonSeattle, United StatesContact: Cadasil ConsortiumTaking people
About the trial
What the trial wants to find out
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
The 4 groups in the trial
- Non-Carrier Cohort
About 100 participants who are at-risk, healthy family members with No NOTCH3 Mutation and no symptoms or signs of cognitive decline.
Treatment: Study Procedures
- Pre-Symptomatic NOTCH3 Cohort
About 133 participants who are pre-symptomatic, at-risk, and healthy (with verified NOTCH3 mutation) family members with no symptoms.
Treatment: Study Procedures
- Symptomatic NOTCH3 Cohort - No Functional Decline
About 134 participants who are symptomatic (with verified NOTCH3 mutation) family members and no functional decline (e.g., mild cognitive impairment (MCI) with premorbid functional levels maintained).
Treatment: Study Procedures
- Symptomatic NOTCH3 Cohort - Functional Decline
About 133 participants who are symptomatic family members with a verified NOTCH3 CADASIL mutation and evidence of functional decline consistent with early dementia.
Treatment: Study Procedures
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Unraveling the Early Phases of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
- Plain-language title
- Studies early changes in CADASIL, an inherited disease affecting brain blood vesselsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 January 2026